Acute disease

This early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a new vaccine called Shigella4V2 to see if it can protect people from shigellosis, a severe diarrheal disease. About 120 healthy adults will receive either the vaccine or a placebo and then be exposed to the bacteria in a controlled setting. The goal is to see if…

This study tests a two-dose vaccine designed to prevent diarrhea from two common types of Shigella bacteria in 8,000 children aged 6 months to 5 years in Bangladesh. Half the children get the vaccine, half get a placebo, and researchers track who gets sick over time. The goal is …

This study tests an experimental nasal vaccine made from a harmless virus (Sendai virus) that is similar to the one causing croup. The goal is to see if it is safe and helps children ages 1 to 5 build protection against croup. About 54 children will receive the vaccine as nose dr…

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This study tests a drug called efgartigimod, given as a shot under the skin, for people who have antibody-mediated rejection after a kidney transplant. The trial includes 30 adults who received a kidney at least 6 months ago and have signs of rejection. Participants will receive …

This Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…

This study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to fi…

This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…

This study tests a non-invasive pneumatic vest designed to apply pressure to the chest wall in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 who are on mechanical ventilators. The goal is to see if the vest can improve oxygen levels in the blood. Up …

This Phase 3 trial is testing whether a targeted immunotherapy drug called blinatumomab, given alongside low-intensity chemotherapy, works better than standard chemotherapy for older adults (55+) with a specific type of acute lymphoblastic leukemia (ALL). The study involves 303 p…

This study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…

This trial tests whether a home-based tele-rehabilitation program is as effective as traditional center-based cardiac rehabilitation for people who have recently had a heart attack (acute coronary syndrome). Participants will either complete 20 sessions at a rehab center or 20 se…

This study tracks how often people get voice box injuries after having a breathing tube for 1 to 7 days in the ICU. It also tests whether a 14-day course of budesonide and azithromycin can help heal those injuries and improve breathing. About 64 adults who had a breathing tube wi…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…

This pilot study aimed to help people who had an opioid overdose by starting them on buprenorphine/naloxone in the emergency room and then connecting them to an addiction clinic. The goal was to reduce repeat overdoses and improve treatment engagement. However, the study was with…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remi…

This early study tests whether the drug theophylline can prevent kidney injury in newborns who experienced oxygen deprivation at birth (HIE) and are receiving cooling therapy. Thirty infants will receive one or two doses of theophylline within 18 hours of birth. The main goal is …

This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This study tests a chemotherapy drug called CPX-351 (Vyxeos) in 25 patients under 22 years old who have secondary myeloid neoplasms, a type of blood cancer that develops after previous cancer treatment. Participants receive one or two rounds of CPX-351, followed by a stem cell tr…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This study tests whether adding two adult cancer drugs, bortezomib and vorinostat, to standard chemotherapy is safe and effective for infants with acute lymphoblastic leukemia (ALL). About 50 newly diagnosed infants will receive the combination. The goal is to see if it reduces l…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combinati…

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This study tests whether adding the drug bortezomib to standard chemotherapy helps children and young adults (ages 1 to 30) with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. About 847 participants received either standard chemo alone or ch…

This phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…

This phase II trial tests a personalized cell therapy called tisagenlecleucel (Kymriah) in children and young adults with high-risk B-cell acute lymphoblastic leukemia who still have detectable cancer cells after initial chemotherapy. The treatment involves collecting the patient…

This study tests a drug called selatogrel, which people inject themselves at the first sign of a heart attack. The goal is to see if it can prevent death or reduce heart damage. The trial involves 25,000 people who recently had a heart attack and have other risk factors. Particip…

This phase II trial is studying a combination of chemotherapy (Hyper-CVAD) and the targeted drug dasatinib, with or without a donor stem cell transplant, in 97 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see how well this approa…

This study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by mai…

This Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…

This study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…

This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…

This study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…

This early-phase trial tests a new cell therapy for people with hard-to-treat T-cell leukemia or lymphoma. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD7 protein, and infuse them back. The main goals a…

This early-phase trial tests whether adding venetoclax to a chemotherapy regimen originally designed for children is safe and effective for adults under 60 with newly diagnosed acute lymphoblastic leukemia (ALL). The study involves 12 participants and focuses on finding the right…

This phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…

This early study tests whether combining a low-dose steroid with the drug ruxolitinib can better control grade II acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body. The trial includes 30 people wit…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …

This phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…

This early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…

This early-phase trial tests a new drug called M3814 alongside three chemotherapy drugs (mitoxantrone, etoposide, and cytarabine) in 48 adults with acute myeloid leukemia that has returned or not responded to treatment. The main goal is to find the safest dose and understand side…

This early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for periods of time. About 60 adults with untreated CLL who need therapy will receive the combination. The goal i…

This phase 2 trial tests whether a combination of two oral drugs, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has either not responded to treatment or returned. About 28 adults will t…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant in adults with acute myeloid leukemia that has returned or not responded to treatment. The goal is to find the safest dose of sorafenib and …

This early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer c…

This early-stage trial tests whether the drug dexmedetomidine can reduce acute kidney injury in 78 adults undergoing ascending aortic surgery with a heart-lung machine. Half receive the drug, half get a placebo. The goal is to see if the drug's anti-inflammatory effects help prev…

This phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells…

This phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatme…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This study tests a drug called felzartamab in people who received a kidney transplant and later developed antibody-mediated rejection (AMR), where the immune system attacks the new kidney. The drug targets immune cells that make harmful antibodies, aiming to reduce kidney damage …

This study tests whether rivastigmine, a drug used for Alzheimer's, can prevent delirium from coming back after initial treatment with physostigmine for anticholinergic poisoning. About 42 people aged 10 and older with controlled delirium will receive either rivastigmine or a pla…

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to…

This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…

This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…

This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …

This study tests whether using a special camera (OCT) inside the heart's arteries during a heart attack procedure leads to better outcomes than the standard X-ray method. About 3000 people having a heart attack will be randomly assigned to one of the two approaches. The goal is t…

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back af…

This study tests the safety of an antibiotic called Vabomere in children aged 3 months to 12 years who have complicated urinary tract infections, including kidney infections. The children receive the medicine through an IV while in the hospital. Researchers monitor for side effec…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …

This study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…

This study compares a targeted immune therapy called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1-30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away long…

This study tests whether adding the drug venetoclax to standard chemotherapy can help treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and adults (18+) whose leukemia has come back or not responded to treatment. The goal is to find…

This study looks at whether placing naloxone—a medication that reverses opioid overdoses—in vending machines makes it easier for people in the community to get it. Researchers will track how many naloxone kits are distributed before and after installing the machines. Anyone in th…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…

This study looks at whether giving people with PTSD a personalized mix of gut bacteria (called pharmabiotics) can help their mental health. The researchers will track changes in PTSD symptoms, anxiety, depression, and thinking skills over 14 days. The goal is to see if fixing the…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study follows about 1,756 adults who were part of a larger trial and received either ketamine or etomidate during emergency intubation. Researchers want to see if ketamine can reduce PTSD symptoms one year later, since it may block the brain's formation of traumatic memories…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted drug (quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo helps control the cancer. About 52…

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …

This study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the…

This study looks at whether children and teens being treated for acute lymphoblastic leukemia can follow a low-glycemic (low-sugar) diet for six months. The goal is to see if this diet is practical and helps manage weight during cancer treatment. About 88 participants will track …

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…

This early-phase trial is testing the drug selinexor (KPT-330) in 16 children and young adults with leukemia that has come back or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has re…

This study tests whether a drug-coated balloon is as safe and effective as a drug-eluting stent for people with large coronary artery disease. About 1,400 participants from multiple countries will be randomly assigned to one of the two treatments. The goal is to see which approac…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This study tests a subcutaneous (under the skin) injection of blinatumomab for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or minimal residual disease. The goal is to see if this new method is safe and effective. About 181 adults and adolescents…

This study tests whether the immunotherapy drug nivolumab can wipe out any leftover leukemia cells and prevent the cancer from returning in people with acute myeloid leukemia (AML) who are already in remission after chemotherapy. The trial enrolled 82 adults whose AML had respond…

This study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…

This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…

This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…

This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before en…

This Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…

This study tests a new treatment called CYP-001 for people who develop a severe immune reaction (graft versus host disease) after a stem cell transplant. About 60 participants will receive either CYP-001 plus standard steroids or a placebo plus steroids. The goal is to see if add…

This phase 3 trial tests whether acalabrutinib is as effective as ibrutinib for people with high-risk chronic lymphocytic leukemia (CLL) who have already tried other treatments. About 533 participants will receive either acalabrutinib or ibrutinib pills. The main goal is to see h…

This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Th…

This early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. T…

This pilot study aimed to test whether a mixture of dexamethasone, hyaluronic acid, and a green dye could be safely injected into the ear to treat certain types of hearing loss that don't improve with standard treatments. The plan was to enroll 26 adults with sudden hearing loss,…

This phase 2 trial tests whether a combination of intravenous immunoglobulin (IVIG) and rituximab can help people with psychosis caused by antibodies attacking the brain. 70 participants with acute psychosis and specific antibodies receive either the immunotherapy or a placebo. T…

This study tests whether giving surfactant (a natural substance that helps lungs stay open) through a small airway device placed above the vocal cords, along with standard breathing support (CPAP), is better than CPAP alone for late preterm and early term infants with respiratory…

This study tests whether the drug APX-115 can prevent kidney injury caused by contrast dye used in heart procedures. About 230 adults with kidney disease will receive either the drug or a placebo before and after their procedure. The goal is to see if the drug reduces kidney dama…

This early-phase trial tests a new drug called ACY-1215 (ricolinostat) combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia has returned after prior treatment. The main goal is to find a safe dose, while also checking if the combination helps …

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This study tests whether infusions of cord blood stem cells can help people with moderate to critical COVID-19 pneumonia. The trial includes 65 adults with COVID-19-related acute respiratory distress syndrome (ARDS). Researchers will compare stem cell treatment plus standard care…

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which com…

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combo is …

This study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood…

This study is testing whether giving each patient on a ventilator a personalized oxygen target (based on their unique health data) leads to better outcomes than standard care. Researchers will compare death rates and time spent on the ventilator between the two groups. The trial …

This phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…

This early-stage trial tests a combination of two drugs, venetoclax and azacitidine, in people with a serious type of myelodysplastic syndromes (MDS) who have not had treatment before. The goal is to find the safest dose and see how well the drugs work together to control the dis…

This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…

This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.

This study aims to find the safest and most effective initial chemotherapy for older adults (60-75) newly diagnosed with acute myeloid leukemia who can handle strong treatment. About 90 participants will be randomly assigned to one of two drug combinations or a standard treatment…

This early-phase study tests a new biologic drug called PIT565 in 61 adults with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see ho…

This phase II trial is testing whether combining venetoclax and azacitidine can help people with therapy-related myelodysplastic syndrome (t-MDS), a blood cancer that develops after prior cancer treatment. The study will enroll 33 adults and measure how many achieve complete remi…

This study tests the drug daratumumab in adults with T-cell acute lymphoblastic leukemia (T-ALL) who still have tiny amounts of cancer cells (called minimal residual disease, or MRD) after standard chemotherapy. The goal is to see if daratumumab can clear these leftover cells and…

This trial aimed to test a new drug called CM313, a CD38-targeting antibody, combined with a chemotherapy regimen inspired by pediatric treatments for adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). The goal was to see if the combination could improve rem…

This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if the combination can shrink or control the cancer. Participants will take the drugs by mout…

This early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participa…

This study tests a subcutaneous (under the skin) injection of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if this easier-to-give form is safe and effective at achieving rem…

This phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…

This early-phase trial is testing whether adding a drug called iadademstat to the standard combination of venetoclax and azacitidine is safe and tolerable for adults with untreated acute myeloid leukemia (AML). About 45 people with intermediate- or high-risk AML will take part. T…

This trial aimed to test the drug ASTX727 (Inqovi) alone or with donor immune cells in people with blood cancers who had a stem cell transplant. The goal was to see if it could control cancer that remained or came back. However, the study was withdrawn before enrolling any patien…

This study tests a computer alert that reminds doctors to prescribe naloxone—a drug that reverses opioid overdoses—alongside high-risk opioid prescriptions. The alert appears when a doctor orders an opioid for patients aged 12-89 (excluding those with cancer or hospice care). Res…

This early-phase study tests a new three-drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment includes a targeted radiation antibody (lintuzumab-Ac-225) plus two oral drugs (venetoclax and ASTX-727).…

This study tests whether combining zanubrutinib (a BTK inhibitor) with rituximab (an antibody) can help control chronic lymphocytic leukemia or small lymphocytic lymphoma in people who have not had treatment before. About 60 participants will receive the combination, and research…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study was designed to test whether an inhaled drug called ZYESAMI could help people with severe COVID-19 avoid getting worse and needing a ventilator. It was a Phase 3 trial, meaning it was in the final stage of testing. However, the study was withdrawn before any participan…

This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…

This early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This phase 2 trial tests whether adding an experimental antibody called cusatuzumab to the standard drugs venetoclax and azacitidine helps people with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 140 adults who cannot have intensive chemotherapy. P…

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This phase 2 trial tests whether adding the targeted antibody tafasitamab to a standard chemotherapy regimen (DA-EPOCH, with or without rituximab) can improve outcomes for adults newly diagnosed with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). Th…

This early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …

This early-phase study tests a custom-made cancer vaccine (DC/AML fusion vaccine) for people with acute myeloid leukemia (AML) who have recently had a stem cell transplant. The vaccine is designed to teach the body's immune cells to recognize and attack remaining leukemia cells. …

This study is testing a chemotherapy plan specially designed for children with Down syndrome who have a new diagnosis of acute lymphoblastic leukemia (ALL). The treatment uses lower doses of certain drugs to reduce side effects while still fighting the cancer. About 60 children a…

This phase 2 trial tests whether a combination of two drugs, venetoclax (a pill) and azacitidine (an infusion), works better than standard intensive chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). The study enrolls 172 fit adults and measures how long t…

This phase 3 trial compares the targeted drug acalabrutinib against two standard combination therapies (idelalisib plus rituximab or bendamustine plus rituximab) in 310 adults with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main …

This trial aimed to test whether umbilical cord stem cells, delivered through a catheter into heart arteries, could safely improve heart function in people with severe heart damage after a major heart attack. It was designed for patients with very weak hearts (ejection fraction b…

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants …

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…

This study aimed to find safe doses of two experimental drugs (lisaftoclax and pelcitoclax) combined with standard FLAG chemotherapy for adults with T-cell acute lymphoblastic leukemia that returned or didn't respond to treatment. The trial was withdrawn before enrolling any part…

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination works better than either drug alone to control the cancer. About…

This early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…

This study was designed to test whether adding an experimental drug and special immune cells to standard care could help critically ill adults with severe pneumonia, especially those with sepsis or lung failure. The trial was withdrawn before enrolling any participants, so no res…

This study was designed to see if adding two immune treatments (NAI and iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or lung failure recover. It planned to enroll ICU patients and follow them for 90 days. However, the study was with…

This study looks at whether a step-by-step care plan (called TheraPPP) helps patients with severe breathing failure (ARDS) survive and spend less time on a ventilator. The plan includes proven treatments like protective ventilation, paralysis, and prone positioning. About 20,000 …

This study tests a new treatment for adults with a specific type of leukemia (Philadelphia chromosome-positive B-ALL). The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this approach is safe and can h…

This study is for people aged 65 and older who have chronic lymphocytic leukemia (CLL) that hasn't been treated yet. It compares three treatment plans: a standard chemo-immunotherapy (bendamustine plus rituximab), a targeted therapy plus immunotherapy (ibrutinib plus rituximab), …

This phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…

This study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…

This trial compares two different chemotherapy and radiation regimens given before a stem cell transplant for adults aged 40-70 with acute lymphoblastic leukemia (ALL) in remission. The goal is to see if a stronger regimen (using total body irradiation and cyclophosphamide) can r…

This study compares two breathing support strategies—prone positioning and high-frequency ventilation—against standard care in 600 children with severe acute respiratory distress syndrome. The goal is to see which approach helps children spend more days off a ventilator within 28…

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…

This study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…

This study tests whether a drug called anakinra, which reduces inflammation, can help prevent heart failure in people who have just had a heart attack. About 84 participants will receive daily injections of anakinra or a placebo for up to 14 days. The goal is to see if blocking i…

This study tested a new drug called ASP2215 against standard chemotherapy in 276 adults with a specific type of acute myeloid leukemia (FLT3-mutated) that had come back or not responded to initial treatment. The goal was to see if ASP2215 helped people live longer (overall surviv…

This study tests an experimental drug called Auxora in 150 adults with acute kidney injury and breathing failure. Patients receive either Auxora or a placebo daily for five days. The goal is to see if Auxora helps patients survive, breathe without a machine, and avoid kidney dial…

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About …

This study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial inv…

This study was designed to test whether IC14, a drug that blocks a key inflammatory signal, could help people with acute respiratory distress syndrome (ARDS). The plan was to give IC14 or a placebo to about 100 ICU patients and see if it reduced time on a ventilator. However, the…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The approach uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main…

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with stan…

This study tests whether giving a personalized dose of a drug called r-ATG before a stem cell transplant helps the immune system recover faster and reduces serious side effects. It includes children and adults with acute leukemia or myelodysplastic syndrome (MDS) receiving a dono…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study compares two ways to decide which blocked arteries to stent in heart attack patients who have multiple blockages. One method uses standard X-ray images; the other uses a computer analysis of those images to measure blood flow. About 1,800 patients will be randomly assi…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This study tests a new way of giving two drugs—venetoclax and azacitidine—to adults with acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to try to reduce infect…

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…

This phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to s…

This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look…

This phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): continuous ibrutinib alone, a fixed-duration combination of venetoclax plus obinutuzumab, or a fixed-duration combination of ibrutinib plus venetoclax. …

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This study tests two drugs, selinexor and venetoclax, given together with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find the safest dose and see how well the combination w…

This phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…

This study tests whether adding the drug midostaurin to standard chemotherapy helps children with a certain genetic type of acute myeloid leukemia (FLT3-mutated AML). About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more …

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…

This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…

This phase 2 trial is testing whether an oral chemotherapy drug called azacitidine (CC-486) can help prevent acute myeloid leukemia from coming back in Chinese patients who are already in complete remission after initial treatment. About 34 participants will receive either the dr…

This early-phase trial tests a combination of two drugs—entrectinib and ASTX727—in people with a specific, hard-to-treat form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study aims to find the safest dose and watch for side effects in 13 a…

This early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…

This study is checking the safety of the drug BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL). The 10 participants have already been treated and are being watched for side effects, especially liver problems. The goal is to better …

This study was designed to compare two ways to treat walled-off necrosis (a pocket of dead tissue) caused by severe pancreatitis. One method uses a scope through the mouth to clean out the pocket, the other uses surgery through the stomach. The goal was to see which approach work…

This early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…

This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This observational study follows 151 Italian adults with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib between May 2021 and April 2022. Researchers want to see how long patients continue the drug and why they might stop, providing real-world insights beyond …

This study tests a new treatment for adults with a type of leukemia (T-ALL) that has come back or not responded to standard therapy. The treatment combines an immunotherapy drug (PD-1 inhibitor) with a targeted drug (venetoclax) and chemotherapy. The goal is to see if this combin…

This study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…

This study tests a structured nutrition plan for 300 ICU patients who had abdominal surgery and cannot eat normally. The plan includes IV nutrition, oral supplements, and a device to measure calorie needs. Researchers will track infections, ICU stay length, and muscle loss to see…

This phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…

This phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA me…

This early-phase study tests a three-drug combination (navitoclax, venetoclax, and decitabine) in adults and teens with acute myeloid leukemia that returned or didn't respond to previous treatment. The goal is to find the safest dose and see if the combo can shrink or control the…

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-phase trial tests two oral drugs—acalabrutinib and ceralasertib—in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has stopped responding to other treatments. The main goal is to check safety and find the right dose. It is not yet known if the combinat…

This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the …

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This study tests whether adding venetoclax to standard chemotherapy (cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. About 232 participants who are already in remission will receive either the combination or chemo alone. The main goal is to…

This phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to…

This early-phase trial is testing a new treatment called MB-CART19.1 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better r…

This pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a …

This early-phase trial tests whether injecting special liver-like cells into the abdominal muscle can help prevent or treat Small-for-Size syndrome, a serious complication that can occur after partial liver surgery. The study involves 12 patients and focuses mainly on safety, che…

This study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…

This early-phase study tests a drug called palbociclib, given alone or with other medicines, in people whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand side effects. About 32 adults with acute myeloi…

This Phase 3 trial tests whether adding budesonide (an anti-inflammatory) to standard surfactant treatment helps extremely preterm babies avoid chronic lung disease or death. About 642 infants born before 29 weeks or weighing under 1000 grams will receive either the combo or surf…

This study planned to test whether cooling the body before and after opening a blocked artery could help people having a heart attack. It was designed to include 80 patients at up to 15 hospitals. However, the trial was withdrawn before anyone was enrolled, so we have no informat…

This study tests a powerful mix of chemotherapy drugs plus a targeted pill (ponatinib) for people with a fast-growing leukemia called Philadelphia chromosome-positive ALL. The goal is to see if this combination can stop the cancer from coming back. About 88 adults with newly diag…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3…

This study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This study tests a new treatment called MC0518 (made from donor cells) in children who have severe graft-versus-host disease (GvHD) after a stem cell transplant and did not get better with steroids. GvHD happens when the donor's immune cells attack the child's body. The trial com…

This phase 2 trial tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can improve outcomes for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls 116 adults aged 18-70 who have a matche…

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.

This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…

This early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…

This study tests whether ambrisentan, a drug approved for lung blood pressure, can help patients with hepatorenal syndrome—a serious kidney problem that can occur in advanced liver cirrhosis. About 54 hospitalized adults will receive either ambrisentan or the standard drug terlip…

This study tests whether adding evolocumab (Repatha) to standard care helps people who recently had a heart attack reach very low LDL cholesterol levels and avoid death or unplanned heart-related hospital stays. About 2,166 participants with STEMI or NSTEMI will be randomly assig…

This study compares taking two blood thinners for just 1 month versus the standard 12 months after getting a heart stent. It involves over 3,700 patients with acute coronary syndrome. The goal is to see if the shorter regimen reduces bleeding risks without increasing heart proble…

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…

This study follows 433 people with chronic pancreatitis who undergo a surgery called TPIAT, where the entire pancreas is removed to stop pain and the patient's own insulin-producing islet cells are infused back to lower diabetes risk. Researchers track pain relief, quality of lif…

This study tests a combination of three drugs (homoharringtonine, venetoclax, and azacitidine) in 40 adults newly diagnosed with a rare and aggressive leukemia called mixed-phenotype acute leukemia (MPAL). The goal is to see if this drug combo can safely help more patients achiev…

This study compares using a manual clot-removal catheter (Export) before standard balloon angioplasty versus angioplasty alone in 300 heart attack patients with completely blocked arteries. The goal is to see if removing the clot first improves blood flow and reduces in-hospital …

This study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…

This study tests a treatment called AUTO1, a type of CAR T cell therapy, in 153 adults whose B cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attac…

This phase II study tests a combination of two drugs, venetoclax and rituximab, in 25 people with chronic lymphocytic leukemia (CLL) that has relapsed or not responded to treatment. The goal is to see how well the combination works and how safe it is. Participants receive venetoc…

This early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …

This phase 2 trial tests whether adding blinatumomab (an immunotherapy) to standard targeted therapy (dasatinib) can improve treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to achieve a deep molecular response without…

This phase II trial is testing whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy can help older adults with B-cell acute lymphoblastic leukemia or lymphoma. The study compares the combination to standard chemo alone in 68 participants. The goal …

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has returned or not responded to treatment. The goal is to see if the combination is safe and can help co…

This phase 1 study tests a combination of two drugs, ibrutinib and obinutuzumab, in 54 people with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main goal is to check safety and find the best dosing schedule. Researchers will also l…

This study tests a new device called enVast that removes blood clots from heart arteries during a severe heart attack (STEMI). About 148 adults with large clots will either get standard care or standard care plus the enVast device. The goal is to see if the device reduces the siz…

This phase 1 trial tests whether the oral drug Inqovi (decitabine/cedazuridine) can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will …

This early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the…

This study tests a device called Infrasensor that may help doctors quickly identify people with severe heart artery blockages. About 350 adults with chest pain will use the device for 5 minutes, and results will be compared to standard heart catheterization. If accurate, it could…

This study aimed to see if an ultrasound score called VEXUS could help detect acute kidney injury in adults after heart surgery. About 20% of patients develop this complication, which raises the risk of death. However, the study was withdrawn before enrolling any participants, so…

This study looks at whether a substance called UDP-glucose in urine can help doctors find kidney injury earlier in children after heart surgery. Current tests often miss early signs, delaying treatment. About 305 children under 8 years old having heart surgery will provide urine …

This study is testing a new finger-prick blood test that measures troponin levels in about 10 minutes, compared to the usual 2-hour lab test. Researchers hope it will help diagnose heart attacks faster and reassure patients who are not having one, allowing them to be discharged s…

This study planned to compare a rapid antigen detection test against the standard PCR test for diagnosing COVID-19 in people who were close contacts of infected patients but had no symptoms. The goal was to see if the quick, inexpensive antigen test could reliably identify contag…

This study is testing whether a special heart scan (dynamic SPECT) can accurately detect remaining blockages in heart arteries after a heart attack, compared to the current standard invasive procedure (FFR). Sixty adults with multiple blocked arteries will receive both tests one …

This study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or …

This study tests whether a drug called deferoxamine can prevent acute kidney injury in adults undergoing heart surgery. The drug works by removing excess iron, which is thought to damage the kidneys during surgery. About 320 participants will receive either the drug or a placebo …

This study tests a non-invasive ear stimulation technique (taVNS) to prevent acute kidney injury in 152 adults having heart surgery with a heart-lung machine. Half receive real stimulation before and after surgery; the other half get a sham. The main goal is to see if fewer peopl…

This study tests whether a computer program that spots early signs of acute kidney injury can improve patient care. Hospitalized adults at risk are randomly assigned to get an early kidney specialist visit or standard care. The goal is to see if early specialist advice can preven…

This trial tests a new inflatable cushion called the BathMat, designed to help reposition patients lying on their stomachs (proned) in the ICU. Proning helps patients with severe breathing problems get more oxygen, but repositioning them every few hours currently requires at leas…

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study tests a therapy called RETELL that helps people with severe mental illness explore and reshape their life stories. The goal is to improve personal recovery, quality of life, and identity. Twenty adults with conditions like schizophrenia, bipolar disorder, or PTSD will …

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…

This study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…

This study tests whether RELiZORB, a cartridge containing fat-digesting enzymes, can help adults with moderate to severe acute pancreatitis tolerate tube feeding better. Fifteen participants in the ICU will receive the device and be monitored for how much nutrition they can take …

This study tests whether a medically supervised 12-week ketogenic diet is practical for 6 adults with PTSD in Germany. The main goal is to see if people can stick to the diet and complete the study. It is not designed to measure how well the diet works for PTSD symptoms, but it m…

This study looks at whether starting palliative care early can help adults with aggressive leukemias or myelodysplastic syndrome (MDS) have a better end-of-life experience. Researchers will compare where patients die (home, hospice, or hospital) and how often they need hospital c…

This small study tests whether group drumming sessions can improve emotional well-being for parents of autistic children. Ten parents will take part in drumming groups and report changes in anxiety, depression, and feelings of belonging. The goal is to see if making music togethe…

This pilot study tests whether a short, 5-session writing therapy called Written Exposure Therapy (WET) is practical and helpful for pregnant or postpartum adolescents and young adults (ages 15-24) with PTSD. The therapy involves writing about traumatic experiences with minimal t…

This study tests whether a high-intensity parenting program can improve learning and school functioning in Latino children being treated for leukemia or lymphoma. About 214 parents and children will take part. Parents in the high-intensity group will receive extra training in ski…

This study compares two treatments for severe tooth pain: vital pulp therapy, which tries to save the tooth's nerve, and standard root canal treatment, which removes it. Researchers will measure pain after 24 hours and one week, and check healing at 6 and 12 months using AI to re…

This study tests whether a special light therapy (transcranial photobiomodulation) used at home can help improve thinking and memory in adults who survived childhood leukemia or Hodgkin lymphoma. About 44 survivors will use a light device on their head while doing brain-training …

This phase II trial tests whether ruxolitinib (Jakafi) can reduce fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet ready for standard treatment. Ten participants will take the drug and report their fatigue levels using a simple questionnaire. The goal is …

This study aimed to see if exercise can improve physical activity and quality of life in children aged 8-18 with acute lymphoblastic leukemia who are on maintenance chemotherapy. Researchers planned to measure changes in quality of life, activity levels, sleep, and fatigue. The s…

This study tests whether giving a thyroid hormone (T3) directly into the lungs can safely improve oxygen levels in adults with acute respiratory distress syndrome (ARDS), a severe lung condition. About 68 critically ill patients on ventilators will either receive the hormone or s…

This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 patients receiving non-intensive therapy will take…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…

This study investigates cognitive problems in intensive care patients with acute respiratory distress syndrome (ARDS) who develop delirium (sudden confusion). Researchers use a non-invasive EEG cap and auditory tests to measure brain activity at the bedside. The goal is to identi…

This study follows 200 adults on ECMO (a heart-lung machine) for severe breathing problems. Researchers track how many get hospital-acquired infections and measure antibiotic levels in their blood and lungs. The goal is to learn more about infections and drug dosing in these crit…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …

This study follows thousands of critically ill adults in intensive care units across China to better understand acute kidney injury (AKI), a common and dangerous complication. Researchers will collect medical data, images, and biological samples to build a large database. The goa…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) in real-life settings in Romania. Researchers will collect data from 250 patients over three years to see how long they stay on the drug, why they stop, and how effective …

This study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…

This study follows over 1,500 young adult survivors of childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma to see how frailty—a measure of physical weakness and vulnerability—changes over five years. Researchers want to know if frailty can predict future chronic h…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study tests a new way to find unstable plaques in the heart arteries of people who come to the emergency room with chest pain but are not having a heart attack. Researchers use a simple calcium scan to group patients by risk, then follow up with special PET scans to see if p…

This study looks at 90 people who recently had a heart attack and have other artery narrowings that may or may not be dangerous. Researchers will use two types of scans—optical coherence tomography (OCT) and magnetic resonance angiography (MRA)—to see if they can tell which narro…

This study looks at sleep problems in adults who had childhood cancer. About 200 survivors of leukemia, brain tumors, or solid tumors will wear sleep monitors and answer questionnaires. The goal is to find out how common sleep disorders are and how they relate to other health iss…

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This study looks at women who have had a heart attack or unstable angina but do not have major blockages in their heart arteries. Doctors will use special imaging techniques, like IVUS and MRI, to find hidden causes such as cholesterol plaque in artery walls or problems with tiny…

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more about the effects of treatment, not to…

This study is testing whether a computer can automatically measure how much lung tissue is damaged in patients with severe breathing problems from COVID-19 or after surgery. Researchers will compare the computer's lung measurements to standard severity scores in 500 patients. The…

This study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …

This study follows up to 90 children and young adults with mitochondrial liver diseases to learn how these conditions progress over time. Researchers will collect medical data and samples to better understand the diseases and find markers that predict outcomes. The goal is to imp…

This study analyzes data from over 377,000 people who had a heart attack and were prescribed blood thinners (clopidogrel, ticagrelor, or prasugrel) in Germany and the United States between 2011 and 2024. Researchers aim to describe how often each drug is used and how much it cost…

This study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…

This study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…

This study examines how different hospital treatments—sedation, temperature control, and blood pressure management—after a cardiac arrest impact kidney function. Researchers will follow 3500 adults who were resuscitated from a heart attack outside the hospital. The goal is to und…

This study looks at whether teaching people who use drugs how to use fentanyl test strips can help prevent overdoses. About 2,400 adults in Ohio will take part at Project DAWN sites. Some will get the test strip education, while others will just get the usual overdose prevention …

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why …

This study tests whether a special PET/CT scan using a radioactive tracer called FLT can measure how well chemotherapy is working in people with newly diagnosed acute myeloid leukemia (AML). The scan lights up fast-growing cancer cells, and researchers want to see if it can predi…

This study looks at whether a tool called the Chelsea Critical Care Physical Assessment tool (CPAx) can accurately track recovery in 120 adults who developed muscle weakness after being on a breathing machine in the ICU. The goal is to find the smallest meaningful improvement tha…

This study follows 90 people who survived severe COVID-19 pneumonia and needed intensive care. Researchers will check their physical health, mental health, and quality of life at 3 months, 6 months, 1 year, and 5 years after leaving the ICU. The goal is to better understand the l…

This study aimed to collect medical information from people who developed unusual blood clots within four weeks of receiving a COVID-19 vaccine. The goal was to better understand any possible link between the vaccine and these rare events. However, the study was withdrawn before …

This study looks at whether a simple bedside lung ultrasound can predict chronic lung disease in premature infants born before 32 weeks. Researchers will perform ultrasounds on 150 babies with breathing problems and track their outcomes. The goal is to see if early ultrasound sco…

This study looks at whether a special heart MRI, done within a week of a heart attack, can help doctors better predict a patient's future health. Researchers will follow 2,000 adults for years to track serious heart events like another attack or heart failure. The goal is to lear…

This study looks back at medical records of 725 older adults (over 65) with acute myeloid leukemia (AML). Researchers want to see if using a special 'fitness' score to choose treatment leads to longer survival. No new treatments are given; the goal is to learn which treatment app…

This pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The go…

This study looks at how quality of life differs among older adults (60+) newly diagnosed with acute myeloid leukemia (AML) who receive either intensive or non-intensive chemotherapy. Researchers aim to build a decision-making model that helps patients and doctors choose treatment…

This study observes how the diaphragm works in 100 adults with acute respiratory failure who need non-invasive breathing support or high-flow oxygen. Researchers use ultrasound to measure diaphragm movement and thickness at different support levels. The goal is to understand how …

This study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…

This study aimed to see if tracking a specific gene mutation (c-Kit) could help predict relapse in acute myeloid leukemia patients. It planned to compare this method with current monitoring techniques. However, the study was withdrawn before enrolling any participants, so no resu…

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study aims to find new biological markers (biomarkers) that can show how active acute porphyria is in the body and how well treatments are working. Researchers will study 50 people with confirmed acute porphyria to measure gene activity related to heme production and stress …

This study planned to test whether giving doctors machine-learning alerts about patient risks after surgery could reduce serious complications like kidney injury or unplanned ICU stays. It was designed for high-risk patients, but the study was withdrawn before enrolling anyone, s…

This study was designed to track the long-term health of hospitalized patients in China who develop acute kidney injury (AKI). Researchers planned to monitor kidney function decline, new heart problems, and death rates over time. However, the study was withdrawn before any partic…

This study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…

This study looks at different training methods for ICU staff to improve how they remove breathing tubes from patients. It involves over 13,000 adults on ventilators for more than 24 hours. The goal is to see if better education and care plans can reduce deaths and increase use of…

This study looks at whether it is safe to wait before giving a second round of chemotherapy to adults newly diagnosed with acute myeloid leukemia (AML), even if a mid-treatment bone marrow biopsy shows some remaining disease. About 60 participants will receive standard first chem…

This study looks at whether advanced monitoring devices can accurately measure blood thickness (hematocrit) and oxygen levels during continuous dialysis in critically ill patients with acute kidney injury or end-stage kidney failure. About 30 adults in the intensive care unit wil…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study tests whether a drug called racecadotril can reduce fluid leakage in skin blisters, as a model for what happens in the lungs during Acute Respiratory Distress Syndrome (ARDS). ARDS is a severe lung injury with no effective drug treatments, where patients' lungs fill wi…

This international registry is collecting information from 2000 people who have had spontaneous coronary artery dissection (SCAD), a rare cause of heart attacks. Researchers will track participants' health over time to better understand the condition and develop best practices fo…

This study is a large international registry that will collect data from up to 130,000 people who have had a heart attack or unstable chest pain. Researchers will track treatments, outcomes, and safety to understand what works best in real-world care. No new drugs or devices are …

This study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—th…

This study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…

This study follows 9 people with transverse myelitis who previously received an experimental cell therapy called Q-Cells®. Researchers will monitor them for 10 years to check for side effects and see if the treatment continues to have any effect. Participants will have regular ex…

This study watches how a high-frequency ventilator (Servo-n HFOV) works in real hospital use for babies with severe breathing failure. About 75 infants will be observed to see if the machine safely helps them get enough oxygen and remove carbon dioxide. The goal is to gather info…

This study looks at 40 people who recently had a heart attack and had one blockage treated. Researchers will use special pressure wires and optical imaging to examine other blockages that were not treated. The goal is to see how many of these leftover blockages are actually dange…

This study follows about 190,000 Korean radiation workers to see if low-dose radiation exposure over time increases the risk of cancer and other diseases. Researchers will link national health records to track health outcomes. The goal is to better understand the long-term effect…

This study looks at how common kidney injury is in newborns in intensive care and what factors increase the risk. Researchers will review medical records of about 4,000 babies from hospitals around the world. The goal is to better understand short- and long-term kidney health, bu…

This study looks at how doctors treat people having a severe heart attack complicated by cardiogenic shock, where the heart can't pump enough blood. Researchers will track 124 patients at 20 U.S. hospitals to see how decisions about using mechanical heart support devices affect s…

This study follows 120 adults with moderate-to-severe ARDS who are on a breathing machine. Researchers use a non-invasive belt (electrical impedance tomography) to track how air and blood flow are distributed in the lungs over time. The goal is to see if different lung function p…

This study is observing 2,000 people who have had a heart attack to collect detailed medical information, images, and blood samples. Researchers will use this data to better understand different types of heart attacks and find new ways to predict and prevent future heart problems…

This study tests a machine-learning tool that gives doctors a pop-up alert when they prescribe opioids to a patient at high risk of overdose. The alert explains why the patient is at risk and suggests safer options, like prescribing naloxone or referring to pain therapy. Research…

This trial compares two types of video laryngoscope blades—hyperangulated and standard geometry—in critically ill adults who need a breathing tube in the emergency department or intensive care unit. About 2,500 participants will be randomly assigned to one blade type. The main go…

This study tests whether acetazolamide, a drug already used for altitude sickness, can reduce inflammation and immune system activation caused by high altitude. Nineteen healthy adults will take either the drug or a placebo before and during a stay at 3800 meters. Researchers wil…

This observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…

This study tests whether a software tool called the Respiratory Knowledge Portal (RKP) can help ICU teams reduce complications in patients on breathing machines. Researchers will collect data from 875 patients to see if the tool improves how alarms are set, helps wean patients of…

This study tests a new, smaller feeding tube with built-in sensors to measure breathing signals in extremely premature babies (under 1000 grams). The current standard tube is too long for these tiny infants, so the new design shortens the sensor spacing to fit better. Ten babies …

This study looks at how the bacteria in the gut (microbiome) are connected to cancer-related symptoms in children aged 5-18 with acute lymphoblastic leukemia. Researchers will collect stool samples and symptom reports at several points during chemotherapy. The goal is to understa…

This study follows 50 athletes who had acute myocarditis (heart muscle inflammation) to see how often they develop dangerous heart rhythms. Participants wear a portable ECG monitor and do a treadmill stress test at 3 months and 1 year after their illness. The goal is to learn mor…

This study aimed to adapt an opioid overdose education and naloxone distribution program for Black church members, including clergy, people with opioid use disorder, and their families. The goal was to reduce stigma and increase overdose reversal skills. However, the trial was wi…

This pilot study tests whether liraglutide (Saxenda), a weight-loss drug, can raise levels of a brain-protective protein called BDNF in 30 people with multiple sclerosis, long-COVID, or leukemia who are overweight and have memory or concentration problems. Participants will injec…

This study follows about 36 children weighing 2.5-10 kg who have acute kidney injury or fluid overload and are treated with the Carpediem continuous renal replacement therapy system. Researchers will track survival, kidney recovery, and hospital stay lengths to see how well the d…

This observational study looks at medical records of 43,000 hospitalized patients to find out how often acute kidney injury (AKI) develops during a hospital stay. Researchers will also compare death rates and readmission rates between patients who develop AKI and those who do not…